Map Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
7
Ending by 2030
Feb 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 6, 2027The maintenance fee for Fluoroergoline analogs (US 9,150,593) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 1 fee due Jun 22, 2027The maintenance fee for Methods and apparatus for delivering aerosolized medication (US 9,216,259) comes due Jun 22, 2027. Unpaid by Dec 22, 2027, it lapses early.
- 1 fee due Jul 5, 2027The maintenance fee for Enhanced eductor design (US 9,227,030) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,994,197 | Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile In force · From the USPTO record | In force | From the USPTO record | |
| US 8,119,639 | Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile In force · From the USPTO record | In force | From the USPTO record | |
| US 10,172,853 | Method of Therapeutic Administration of Dhe to Enable Rapid Relief of Migraine While Minimizing Side Effect Profile In force · Low confidence | In force | Low confidence | |
| US 8,475,845 | Method of particle formation In force · From the USPTO record | In force | From the USPTO record | |
| US 8,148,377 | Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile In force · From the USPTO record | In force | From the USPTO record | |
| US 9,216,259 | Methods and apparatus for delivering aerosolized medication In force · From the USPTO record | In force | From the USPTO record | |
| US 9,480,803 | Dose counter with lockout mechanism In force · From the USPTO record | In force | From the USPTO record | |
| US 8,517,009 | Methods and apparatus for delivering aerosolized medication In force · From the USPTO record | In force | From the USPTO record | |
| US 8,604,035 | Fluoroergoline analogs In force · From the USPTO record | In force | From the USPTO record | |
| US 8,927,567 | Novel Fluoroergoline Analogs In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 18: 13 lapsed for an unpaid fee · 9 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
35 no status recorded